Show simple item record

Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg)

dc.contributor.authorNyssen, Olga P.
dc.contributor.authorVaira, Dino
dc.contributor.authorSaracino, Ilaria Maria
dc.contributor.authorFiorini, Giulia
dc.contributor.authorCaldas, María
dc.contributor.authorBujanda, Luis
dc.contributor.authorPellicano, Rinaldo
dc.contributor.authorKeco-Huerga, Alma
dc.contributor.authorPabón-Carrasco, Manuel
dc.contributor.authorSusanibar, Elida Oblitas
dc.contributor.authorDi Leo, Alfredo
dc.contributor.authorLosurdo, Giuseppe
dc.contributor.authorPérez-Aísa, Ángeles
dc.contributor.authorGasbarrini, Antonio
dc.contributor.authorBoltin, Doron
dc.contributor.authorSmith, Sinead
dc.contributor.authorPhull, Perminder
dc.contributor.authorRokkas, Theodore
dc.contributor.authorLamarque, Dominique
dc.contributor.authorCano-Català, Anna
dc.contributor.authorPuig, Ignasi
dc.contributor.authorMégraud, Francis
dc.contributor.authorO’morain, Colm
dc.contributor.authorGisbert, Javier P.
dc.date.accessioned2023-03-11T00:04:41Z
dc.date.available2023-03-11T00:04:41Z
dc.date.issued2022-03-16
dc.identifier218933539
dc.identifier8a14aa35-2c32-49bd-a7e6-88629abf2d85
dc.identifier85126625869
dc.identifier.citationNyssen , O P , Vaira , D , Saracino , I M , Fiorini , G , Caldas , M , Bujanda , L , Pellicano , R , Keco-Huerga , A , Pabón-Carrasco , M , Susanibar , E O , Di Leo , A , Losurdo , G , Pérez-Aísa , Á , Gasbarrini , A , Boltin , D , Smith , S , Phull , P , Rokkas , T , Lamarque , D , Cano-Català , A , Puig , I , Mégraud , F , O’morain , C & Gisbert , J P 2022 , ' Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg) ' , Journal of Clinical Medicine , vol. 11 , no. 6 , 1658 . https://doi.org/10.3390/jcm11061658en
dc.identifier.issn2077-0383
dc.identifier.urihttp://aura-test.abdn.ac.uk/handle/2164/19467
dc.descriptionFunding Information: Conflicts of Interest: Gisbert has served as speaker, consultant, and advisory member for or has received research funding from Mayoly, Allergan, Diasorin, Gebro Pharma, and Richen. Nyssen has received research funding from Mayoly and Allergan. Pérez-Aisa has received compensation from Allergan and Mylan for formative actions. A. Di Leo served as consultant for T.H.D. spa. The remaining authors declare no conflict of interest. Funding Information: Funding: This project was promoted and funded by the European Helicobacter and Microbiota Study Group (EHMSG), the Spanish Association of Gastroenterology (AEG) and the Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd). Funding Information: This project was promoted and funded by the European Helicobacter and Microbiota Study Group (EHMSG), the Spanish Association of Gastroenterology (AEG) and the Centro de Investigaci?n Biom?dica en Red de Enfermedades Hep?ticas y Digestivas (CIBERehd). Publisher Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland.en
dc.format.extent1531117
dc.language.isoeng
dc.relation.ispartofJournal of Clinical Medicineen
dc.subjectBismuthen
dc.subjectCultureen
dc.subjectEradication failureen
dc.subjectH. pylorien
dc.subjectHelicobacter pylorien
dc.subjectHp-EuRegen
dc.subjectRescueen
dc.subjectRifabutinen
dc.subjectTreatmenten
dc.subjectR Medicineen
dc.subjectGeneral Medicineen
dc.subject.lccRen
dc.titleExperience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg)en
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Applied Medicineen
dc.description.statusPeer revieweden
dc.identifier.doi10.3390/jcm11061658
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85126625869&partnerID=8YFLogxKen


Files in this item

Thumbnail
Name:
Kaushik_etal_ESPL_Long_Term_Sp ...
Size:
745.7Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record